Lucid Medical Writing
 
   
 
Matt Lewis PhD
 
Publication acknowledgements


First human study of the investigational sedative and anesthetic drug AZD3043: a dose-escalation trial to assess the safety, pharmacokinetics, and efficacy of a 30-minute infusion in healthy male volunteers. Kalman S, et al. Anesth Analg 2015 [Epub ahead of print]
[PubMed]

A bolus and bolus followed by infusion study of AZD3043, an investigational intravenous drug for sedation and anesthesia: safety and pharmacodynamics in healthy male and female volunteers. Norberg Å, et al. Anesth Analg 2015 [Epub ahead of print] [PubMed]

Tremelimumab: a review of development to date in solid tumors. Tarhini AA. Immunotherapy 2013;5:215–29 [PubMed]

Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours. Kaye S, et al. Br J Cancer 2012;106:1728–34 [Free full text]

First report of the safety, tolerability, and pharmacokinetics of the Src kinase inhibitor saracatinib (AZD0530) in Japanese patients with advanced solid tumours. Fujisaka Y, et al. Invest New Drugs 2012;31:108–14 [PubMed]

Pharmacological cardioversion of atrial fibrillation – a double-blind, randomized, placebo-controlled, multicentre, dose‑escalation study of AZD1305 given intravenously. Rσnaszιki A, et al. Europace 2011;13:1148–56 [Free full text]

QT response after a test dose and during maintenance therapy with AZD1305 in patients with atrial fibrillation: a double‑blind, randomized, placebo-controlled trial. Egstrup K, et al. Am J Cardiovasc Drugs 2011;11:199–208 [PubMed]

Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple ascending dose phase I trial. Hannon RA, et al. J Bone Miner Res 2010;25:463–71 [PubMed]

A randomized invasive cardiac electrophysiology study of the combined ion channel blocker AZD1305 in patients after catheter ablation of atrial flutter. Toivonen L, et al. J Cardiovasc Pharmacol 2010;56:300–8 [PubMed]

Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours.
Boss DS, et al. Ann Oncol 2010;21:884–94
[Free full text]

Phase I safety, pharmacokinetics, and inhibition of Src activity study of saracatinib in patients with solid tumors.
Baselga J, et al. Clin Cancer Res 2010;16:4876–83
[Free full text]

Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial. James ND, et al. Eur Urol 2009;55:1112–1123 [PubMed]

Rapid conversion of persistent atrial fibrillation to sinus rhythm by intravenous AZD7009. Geller JC, et al. J Clin Pharmacol 2009;49:312–22 [PubMed]

Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Green TP, et al. Mol Oncol 2009;3:248–61 [PubMed]

Zibotentan. James ND and Growcott JW. Drugs Fut 2009;34:624–34 [Journal]

[Poster] First report of the safety, tolerability, and pharmacokinetics of saracatinib (AZD0530) in Japanese patients with advanced solid tumours. Onozawa Y, et al. Eur J Cancer 2011;47(Suppl 1):S160